MX2009009703A - Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo. - Google Patents

Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.

Info

Publication number
MX2009009703A
MX2009009703A MX2009009703A MX2009009703A MX2009009703A MX 2009009703 A MX2009009703 A MX 2009009703A MX 2009009703 A MX2009009703 A MX 2009009703A MX 2009009703 A MX2009009703 A MX 2009009703A MX 2009009703 A MX2009009703 A MX 2009009703A
Authority
MX
Mexico
Prior art keywords
methyl
solid preparation
fluorobenzonitrile
pyrimidinyl
amino
Prior art date
Application number
MX2009009703A
Other languages
English (en)
Inventor
Yusuke Murakawa
Miyuki Hohokabe
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2009009703A publication Critical patent/MX2009009703A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una preparación sólida que contiene el 2-[[6-[(3R)-3-amino-1-piperidinil]-3,4-dihidro-3-metil -2,4-dioxo-1(2H)-pirimidinil]metil]-4-fluorobenzonitrilo compuesto (A) o una sal del mismo en la forma de un ingrediente farmacéuticamente activo. En forma específica, la presente invención proporciona una preparación sólida que contiene un gránulo compuesto del compuesto (A) o una sal del mismo, y un aditivo (excluyendo celulosa microcristalina) y una tableta que contiene (a) un gránulo que contiene el compuesto (A) o una sal del mismo, y celulosa microcristalina, y (b) un auxiliar de generación de tabletas que contiene estearato de magnesio y celulosa microcristalina.
MX2009009703A 2007-03-13 2008-03-12 Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo. MX2009009703A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007064245 2007-03-13
PCT/JP2008/055016 WO2008114800A2 (en) 2007-03-13 2008-03-12 Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile

Publications (1)

Publication Number Publication Date
MX2009009703A true MX2009009703A (es) 2010-03-03

Family

ID=39409986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009703A MX2009009703A (es) 2007-03-13 2008-03-12 Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.

Country Status (10)

Country Link
US (1) US7994183B2 (es)
EP (1) EP2120885A2 (es)
JP (1) JP5432720B2 (es)
AR (1) AR065698A1 (es)
CA (1) CA2680684A1 (es)
CL (1) CL2008000727A1 (es)
MX (1) MX2009009703A (es)
PE (1) PE20090015A1 (es)
TW (1) TW200900094A (es)
WO (1) WO2008114800A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
US20120129878A1 (en) * 2009-07-28 2012-05-24 Takeda Pharmaceutical Company Limited Tablet
US20120219623A1 (en) 2009-10-02 2012-08-30 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising bi-1356 and metformin
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN102791701B (zh) 2009-12-30 2014-02-12 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
WO2013172297A1 (ja) * 2012-05-14 2013-11-21 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013179307A2 (en) * 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
JP6122879B2 (ja) * 2012-06-05 2017-04-26 武田薬品工業株式会社 固形製剤
EP2769712A1 (en) * 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
TWI707682B (zh) * 2014-07-07 2020-10-21 瑞士商瑞科戴迪股份有限公司 醫藥劑型
CN104825413B (zh) * 2015-05-25 2019-12-20 浙江华海药业股份有限公司 一种含有琥珀酸曲格列汀的口服片剂及其制备方法
CA2987850A1 (en) * 2015-06-17 2016-12-22 Hexal Aktiengesellschaft Alogliptin formulation
CN105596341B (zh) * 2016-03-14 2018-08-10 石家庄四药有限公司 一种琥珀酸曲格列汀固体制剂及制备方法
WO2022208096A1 (en) 2021-04-01 2022-10-06 Sun Chemical Corporation Aqueous inkjet compositions comprising hydroxy-functional polyurethane dispersions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
CA1338596C (en) * 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production
JP3004758B2 (ja) * 1991-04-17 2000-01-31 旭化成工業株式会社 結合性、崩壊性に優れる加工澱粉
NZ540664A (en) * 2002-12-16 2007-09-28 Kissei Pharmaceutical Solid drug for oral use
EP1715893B8 (en) 2004-01-20 2009-12-16 Novartis Ag Direct compression formulation and process
CA2554809C (en) * 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
AU2004318013B8 (en) * 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2622472C (en) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
AU2007296556B2 (en) 2006-09-13 2013-09-19 Takeda Pharmaceutical Company Limited Use of 2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
PE20081734A1 (es) * 2007-02-01 2009-01-19 Takeda Pharmaceutical Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
UY31290A1 (es) * 2007-08-16 2009-03-31 Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido

Also Published As

Publication number Publication date
PE20090015A1 (es) 2009-01-30
JP2010521416A (ja) 2010-06-24
CA2680684A1 (en) 2008-09-25
US7994183B2 (en) 2011-08-09
TW200900094A (en) 2009-01-01
US20100105710A1 (en) 2010-04-29
JP5432720B2 (ja) 2014-03-05
WO2008114800A3 (en) 2008-12-24
CL2008000727A1 (es) 2008-10-17
WO2008114800A2 (en) 2008-09-25
EP2120885A2 (en) 2009-11-25
AR065698A1 (es) 2009-06-24
WO2008114800A8 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
MX2009009703A (es) Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.
MX2012001284A (es) Tableta.
GEP20125410B (en) Solid preparation comprising alogliptin and pioglitazone
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
MX2010004232A (es) Compuesto de indolina de pirimidilo.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
SI1771178T1 (sl) Uporaba K-252a in kinaznih inhibitorjev za preprečevanje ali zdravljenje patologij, povezanih s HMGB1
IL180597A0 (en) Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
MY146947A (en) Antiparasitic agent for fish and method of controlling proliferation of fish parasites
MY155938A (en) Oral pharmaceutical composition
TW200730176A (en) Formulations of quinolinones
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
WO2009060952A1 (ja) 新規製剤
MX2007013468A (es) Composiciones que contienen tanaproget micronizado.
SI1994926T1 (sl) Farmacevtske oblike valsartana
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
TW200744583A (en) Statin stabilizing dosage formulations
WO2009106960A3 (en) Stable compositions of lamivudine, tenofovir and efavirenz
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
TW200722076A (en) Composition for increasing anti-oxidation activity in blood

Legal Events

Date Code Title Description
FG Grant or registration